Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting

Description

This study evaluates the efficacy of auricular percutaneous electrical nerve field stimulator in children, adolescents and young adults with chemotherapy induced nausea and vomiting.

Conditions

Chemotherapy-induced Nausea and Vomiting

Study Overview

Study Details

Study overview

This study evaluates the efficacy of auricular percutaneous electrical nerve field stimulator in children, adolescents and young adults with chemotherapy induced nausea and vomiting.

Efficacy of Auricular Neurostimulation for Children Adolescents and Young Adults With Chemotherapy Induced Nausea and Vomiting

Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting

Condition
Chemotherapy-induced Nausea and Vomiting
Intervention / Treatment

-

Contacts and Locations

Milwaukee

Children's Wisconsin Hospital, Milwaukee, Wisconsin, United States, 53226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subjects who are scheduled to be admitted for chemotherapy administration and who will have at least one additional cycle of the same chemotherapy
  • * Chemotherapy regimens must include moderate and/or severe emetogenic chemotherapy
  • * Significant developmental delays that would prohibit participation
  • * Infection or severe dermatological condition of ear
  • * Uncontrolled or severe infection
  • * No implanted electrical device is permitted
  • * Pregnancy
  • * Severe cardiopulmonary disease
  • * Diagnosis of hemophilia or other bleeding disorders
  • * Diagnosis psoriasis vulgaris

Ages Eligible for Study

4 Years to 30 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Medical College of Wisconsin,

Study Record Dates

2025-04-29